The study findings indicated the following rates of hematologic toxicities associated with mTOR inhibitors: anaemia in 38.8%, with 7.5% of patients experiencing severe anaemia; leucopenia in 19.6%, with 1.8% of patients experiencing severe leucopenia; and neutropenia in 14.9%, with 5.6% of patients experiencing severe neutropenia [161]. The gene discussed is MTOR; the disease is anemia (phenotype).